Shopping Cart
Remove All
Your shopping cart is currently empty
Erlizumab is a humanized monoclonal antibody directed against the integrin beta-2 subunit (CD18). By blocking the interaction between CD18 on leukocytes and adhesion molecules on vascular endothelial cells, this antibody effectively inhibits inflammatory cell recruitment and infiltration, thereby reducing tissue damage in myocardial reperfusion injury.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | Erlizumab is a humanized monoclonal antibody directed against the integrin beta-2 subunit (CD18). By blocking the interaction between CD18 on leukocytes and adhesion molecules on vascular endothelial cells, this antibody effectively inhibits inflammatory cell recruitment and infiltration, thereby reducing tissue damage in myocardial reperfusion injury. |
| Synonyms | rhuMAb |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | Integrin b2/ITGB2/CD18 |
| Cas No. | 211323-03-4 |
| Isotype | IgG1 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.